Advances in therapeutics have led to improvements in both survival and quality of life for men with advanced or metastatic prostate cancer. Get the latest information about how physicians can now more clearly detect where the prostate cancer has traveled in the body, prostate specific membrane antigen (PSMA)-directed therapies, immunotherapies, and other targeted therapies and promising novel agents for patients.
Matthew Dallos, MD
Dr. Matthew Dallos is a medical oncologist and Assistant Professor of Medicine at Columbia University Medical Center who specializes in the treatment of prostate cancer. He is an expert in prostate cancer immunotherapy and his research focuses on harnessing the immune system for the treatment of both localized and metastatic disease. He previously discovered several key mechanisms in which androgen deprivation therapy (ADT) modulates the immune system. These findings are now being translated into a number of ongoing innovative clinical trials that he leads as principle investigator. His ultimate goal is to improve both the quality of life and the chance for cure for men living with prostate cancer.

Dr. Dallos received his bachelor’s degree in neuroscience from Brown University. He earned his MD with distinction in research from Northwestern University where he was also a HHMI Research Scholar. He completed his internship and resident at NYU followed by medical oncology fellowship at Columbia University. He has received numerous awards including an ASCO Young Investigator Award, PCF Young Investigator Award and PCF/Movember Challenge Award.
Michael Morris, MD
Dr. Morris is a prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan-Kettering Cancer Center, where he was the Chief Fellow as well.

Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radioimmunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.

In addition, he is the Medical Director of the Prostate Cancer Clinical Consortium, and chairs the GU Committee of the Alliance for Oncology Trials in Oncology, an NCI-funded cooperative group for the conduct of cancer clinical trials.
David Nanus, MD
Dr. David Nanus is an internationally recognized leader in the treatment and care of patients with genitourinary (GU) cancers, including cancers of the prostate, kidney, bladder and testes. He is actively involved in clinical, translational and basic research in GU malignancies, serving as principle or co-investigator on a variety of clinical research trials that incorporate novel targeted therapies for his patients. Dr. Nanus is Director of the NewYork-Presbyterian and Weill Cornell Medicine Healthcare Services Cancer Program, a program unifying oncology and hematology clinical care and research at NewYork-Presbyterian’s regional hospitals. He previously served as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian.
Susan Slovin, MD, PhD
Dr. Susan Slovin is an Attending Physician in the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and a Professor of Medicine at Weill Cornell Medical College. She is a board-certified medical oncologist with expertise in the areas of prostate cancer immunology and clinical trial design. A noted immunologist, she leads an initiative that focuses on the development of novel immunologic approaches for the treatment of prostate cancer. This includes assuming leadership of the Prostate Immunotherapy Group, sponsored by the Prostate Cancer Foundation, whose challenge is to develop guidelines for development of immune therapy clinical trials in prostate cancer.
Mark Stein, MD
Dr. Mark Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in the field of genitourinary oncology, treating patients with prostate, kidney, bladder and testicular cancers. In addition to providing standard therapies for the treatment of genitourinary cancers, such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator-initiated and industry-sponsored clinical trials. He has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer, as well as in men with advanced prostate cancer.
Cora Sternberg, MD
Dr. Cora Sternberg is a Professor of Medicine and the Clinical Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine, Sandra and Edward Meyer Cancer Center and NewYork-Presbyterian Hospital. Dr. Sternberg is an internationally respected leader in the fields of medical oncology and urological malignancies and a recognized expert in the area of new drug development, particularly known for her publications on novel therapies for prostate cancer. She is the principal investigator for numerous studies and has lectured at universities and cancer symposia worldwide. Dr. Sternberg has published extensively and is an associate editor and editorial board member of several international journals.
Scott Tagawa, MD
Dr. Scott Tagawa is a Professor of Medicine and Urology at Weill Cornell Medicine, as well as an Attending Physician at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney and bladder cancer, as well as in the prevention and treatment of thrombosis with cancer. Dr. Tagawa is the Weill Cornell principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB) where he also serves on the Board of Directors, and is a member of the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology (ASCO). Additionally, Dr. Tagawa serves on the editorial boards of many journals, and is a member of numerous national and international medical and scientific societies.
Register To Watch Recording
Full name*
Email Address*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.